explore -WSS

explore

author：leisure time 2025-09-28 01:38:00 - browse：354

Adam's take main illustration — Molly Ferguson/STAT

Hello! Some takes and thoughts on Gilead’s Trodelvy troubles, Elevation Oncology’s surprising rise, and Kura Oncology’s “wall-crossing” stock sale.

Gilead needs Arcellx more than ever

The clinical trial setback for Trodelvy in non-small cell lung cancer reported by Gilead Sciences on Monday was another dose of bad news for the company’s oncology business. Strategically, does it make sense for Gilead to invest even more in antibody-drug conjugates like Trodelvy, where its lackluster profile and increased competition overall makes winning seem unlikely? Or, should Gilead double down on its Kite division and CAR-T cell therapy — the type of cancer treatments where it truly excels?

If the answers to those questions are no and yes (I lean that way), then Gilead’s current partnership with Arcellx, which is developing a BCMA-targeted CAR-T therapy for multiple myeloma, becomes a lot more important.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Weight loss drugs should be covered by insurers, AMA says

focus

WSS

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

Ventyx halts psoriasis drug development after lackluster trial results

WuXi Biologics beefs up its lobbying operation

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

ALS treatment from Biogen, Ionis fails in study

What is STAT's opinion section for?

Wikipedia

explore

Gilead needs Arcellx more than ever

hotspot

State Dept. review finds Biden bears some blame for Afghanistan failures

Cancer diagnosis changes perspective doctor, former hospital CEO

Moonlake's readout produced a cash windfall. Risks remain

Hottest summer in 2,000 years puts focus on extreme heat, health

Guidelines to prevent youth baseball injuries need more muscle

What a koala virus tells us about the human genome

Peter Hotez and the public health issue of online harassment

Free medical tuition alone isn't enough to close gaps in primary care

As demand for Covid shots wanes, Moderna seeks its next success

White House drug czar issues call for 'recovery

leisure time

Type 2 diabetes prevention programs work at large scale: study

Free medical tuition alone isn't enough to close gaps in primary care

Novo Nordisk testing Wegovy against alcohol

STAT reporters are Pulitzer Prize finalists for investigative reporting

Fertility clinic egg and embryo storage is a disaster

UnitedHealth sued over use of algorithm in Medicare Advantage plans

hotspot

focus

focus

hotspot